STAT May 24, 2024
The MDMA study was her last hope. She had read headlines celebrating a 83% response rate in one small, early study of the psychedelic for treating PTSD, and was counting on the new clinical trial to alleviate her own post-traumatic stress disorder. Instead, after her first MDMA session, she felt intense despair when her symptoms didn’t dissipate.
She described standing on a train platform, while on the phone with her study therapists, and considering jumping in front of a train, according to a video of the participant describing the experience at a 2016 conference on psychedelic therapy that STAT has seen. “For the first time in a really long time I went, ‘I am done,’” she told the audience. “All...
Today's Sponsors
Today's Sponsor